



PRESS RELEASE

Braun Beteiligungs GmbH (BBG) invests in Enzymicals AG

- **Participation agreement signed on June 8th 2012 in Greifswald**
- **Stronger collaboration between Enzymicals AG, Herbrand PharmaChemicals GmbH and BRAIN AG**

Greifswald, June 18th, 2012 - Braun Beteiligungs GmbH (BBG) has acquired a stake in Enzymicals AG. The participation agreement was signed on 8th of June 2012. This growth financing will further expand the collaboration of Enzymicals AG, Herbrand PharmaChemicals GmbH and BRAIN AG. BRAIN AG has also invested an additional sum, thereby underscoring the significance of the alliance.

Commenting on his company's important step toward the future, Ulf Menyes, CEO of Enzymicals AG, noted: "We at Enzymicals AG are delighted that we have made further progress in expanding our intense customer relationships on the chemicals/pharmaceuticals market by the investment from BBG.

The positive effects that will result from closer collaboration with Herbrand PharmaChemicals GmbH in market-orientated biocatalytic process development and with BRAIN AG in enzyme identification will be very beneficial to all parties involved. We are now presenting ourselves as a strong alliance on the market. In order to meet the resulting higher standards, expanding the growth financing by increasing the capital is a logical step for our company."

Contact

Enzymicals AG

Dr Ulf Menyes
CEO
Walther-Rathenau-Str. 49a
17489 Greifswald
Germany

Tel: +49 383 451 5470
Fax: +49 383 451 5473
E-mail: ulf.menyese@enzymicals.com
Web: www.enzymicals.com

**Visit us at the
Achema 2012, Frankfurt/M.
Halle 9.2 Stand C62**



The BBG alliance includes Herbrand PharmaChemicals GmbH, Riemser Arzneimittel GmbH, Cheplapharm Arzneimittel GmbH and WALTER RITTER GmbH & Co. KG.

Norbert Braun, commercial manager of BBG, commented: “BBG’s stake in Enzymicals AG is a reasonable addition to our portfolio in the pharmaceutical industry. We will use the synergies created by our investments in this area to present our companies with a forward-looking focus on the market. We will concentrate on pioneering and innovative technologies such as biocatalysis. This is firmly established in the market environment of industrial biotechnology, generates high growth rates and is thus a logical further step for our strategy in this segment.”

The growth financing will help the collaboration of Enzymicals, BRAIN and Herbrand PharmaChemical to progress further.

The core competencies of the companies complement each other very well. BRAIN AG identifies, optimises and produces new enzymes. Enzymicals AG handles application and process development of biocatalytic processes for chemical and pharmaceutical products and process-orientated enzyme optimisation. As the final step, there is Herbrand PharmaChemicals GmbH’s biocatalytic production of active pharmaceutical ingredients (APIs) in compliance with GMP. This company alliance represents an unique value chain, from new enzymes to chemical/pharmaceutical products produced with biocatalysis (including the option to manufacture the complete drug within the network).

Jürgen Eck, CTO of BRAIN AG, noted: “The collaboration with BBG is a major step for all parties towards reinforcing our international competitive edge in the field of industrial biocatalysis for chemical/pharmaceutical applications. We feel that the partnership will open up completely new opportunities to give the products and processes from industrial biocatalysis the attention they deserve. Our



collaboration will provide us with direct access to the international markets.”



About Enzymicals AG

Enzymicals AG, Greifswald, a spin-off from the group of Prof. Bornscheuer, is specialized in the production of unique biocatalysts and the biocatalytic production of fine and specialty chemicals in up to kilogram scale. The company therefore works in close collaboration with leading enterprises of the chemical, pharmaceutical and biotech industry, such as Evonik, Lonza and Sigma-Aldrich for example.

www.enzymicals.com

About Braun Beteiligungs GmbH and Herbrand PharmaChemicals GmbH

Braun Beteiligungs GmbH (BBG) is a medium-sized shareholding company with its origin in the year 1973.

The BBG holds a major share of Herbrand PharmaChemicals GmbH from Gengenbach.

Herbrand is a specialized production facility for fine chemicals especially for the use in pharmaceutical industry.

www.braun-beteiligungen.de

www.herbrand-hpc.de

About BRAIN AG

BRAIN AG belongs to Europe's leading companies in the field of "white" biotechnology. In the framework of so far more than 60 strategic cooperations BRAIN AG identifies and develops innovative products and solutions for companies in the areas of chemistry, pharmaceuticals, cosmetics and food, based on microbial diversity available in nature but so far unexplored. The active product compounds are determined in BRAINs own "BioArchive", which is amongst the most comprehensive archives of its kind.

www.brain-biotech.de

Images (printing permitted provided source is acknowledged)



Image

Shareholders of Enzymicals (from left to right: Dr. Ulf Menyes, Prof. Udo Kragl, Dr. Marlen Schmidt, Dr. Jürgen Eck, Dr. Dagmar Braun, Prof. Uwe Bornscheuer, Dr. Rainer Wardenga)

© Enzymicals AG, Greifswald

Images and text are also available at www.enzymicals.com.